EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe

Colleen Davenport iD, Patricia Gravel, Yamei Wang, Setareh A Williams, Alethea Wieland, Bruce Mitlak

Therapeutic Innovation & Regulatory Science · 2024

DOI: 10.1007/s43441-024-00616-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Colleen Davenport und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radius Health, Inc., 22 Boston Wharf Road, 7th Floor, Boston, MA, 02210, USA. cdavenport@radiuspharm.com. Hauptthemen laut MEDLINE: Drug Approval, Osteoporosis, Parathyroid Hormone-Related Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real-World Evidence (RWE), which has historically been used to support post-approval safety studies, has recently gained acceptance for new drug applications as supportive evidence or as new clinical evidence for medicinal products with orphan designation and/or in disease areas with high unmet need. Here, we present a case study for the use of RWE in the approval of abaloparatide in the European Union (EU) under the tradename Eladynos. In addition to data from the pivotal Phase 3 study, the marketing authorization application (MAA) included clinical data from additional interventional and observational studies, as well as post-marketing data obtained from the United States (US) market since approval of abaloparatide by the Food and Drug Administration (FDA) in 2017. The new interventional studies were not designed to assess fracture efficacy and cardiovascular safety which were topics of concern raised by the Committee for Medicinal Products for Human Use (CHMP) during their review of the initial MAA submitted in 2015. However, these studies taken together with the RWE formed the basis for a new MAA. Prior to the planned resubmission in the EU, national Scientific Advice (SA) was sought on the proposed clinical program, specifically on the relevance of Real-World Data (RWD) derived from an observational study to support and complement the efficacy and safety data already available from prospective randomized clinical trials. This case study demonstrates successful use of RWE to address a previously identified gap raised by the CHMP during the review of an earlier MAA, which led to the approval of Eladynos for the treatment of osteoporosis in the EU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalOsteoporosisParathyroid Hormone-Related ProteinHumansBone Density Conservation AgentsEuropean UnionEuropeUnited States Food and Drug AdministrationUnited States

Stichwörter der Autor:innen

AbaloparatideEMAEladynosFDAOsteoporosisReal-world dataReal-world evidenceRegulatory decision makingTymlos

Substanzen

abaloparatideBone Density Conservation AgentsParathyroid Hormone-Related Protein

Autor:innen und Institutionen

  • Radius Health, Inc., 22 Boston Wharf Road, 7th Floor, Boston, MA, 02210, USA. cdavenport@radiuspharm.com.
  • Triskel Integrated Services, Le Grand-Saconnex, Switzerland.
  • Radius Health, Inc., 22 Boston Wharf Road, 7th Floor, Boston, MA, 02210, USA.
  • Star Biopharma Consulting, Malvern, PA, USA.
  • Clinical Research Strategies, Wexford, PA, USA.

ORCID-Profile: Colleen Davenport

Zitieren

APA

Davenport, C., Gravel, P., Wang, Y., Williams, S. A., Wieland, A., & Mitlak, B. (2024). Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00616-7

Vancouver

Davenport C, Gravel P, Wang Y, Williams SA, Wieland A, Mitlak B. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00616-7

BibTeX
@article{Davenport2024,
  author = {Davenport, Colleen and Gravel, Patricia and Wang, Yamei and Williams, Setareh A and Wieland, Alethea and Mitlak, Bruce},
  title = {Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2024},
  doi = {10.1007/s43441-024-00616-7}
}
Kostenlos starten →